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It has  been  hypothesized  that  genomic  instability is 
an  important  component  of  tumorigenesis.  In  an at- 
tempt to establish  this  relationship,  we  determined  the 
frequencies  with  which two nontumorigenic  and  four 
tumorigenic rat liver  epithelial cell lines  underwent a 
particular  type  of  genetic  instability,  gene  amplifica- 
tion. By exposing cells to N-(phosphonoacety1)-L-as- 
partate (PALA), a drug  which  specifically  inhibits  the 
aspartate transcarbamylase  activity of the multifunc- 
tional CAD  enzyme and selects for  amplification of the 
CAD  gene, we observed a striking parallel between  the 
ability of these cell lines to become resistant to this 
drug  and  the  ability  of  these  same  cells  to  form  tumors 
after  injection into day-old  syngeneic rats. Cells  of one 
highly tumorigenic line became resistant to PALA 
greater than 70 times  more  often  than  those of a non- 
tumorigenic line. Molecular analyses of eight inde- 
pendent  PALA-resistant  subclones  confirmed  that,  in 
each case, this  resistance was due to amplification  of 
the CAD gene. Thus,  our  results  demonstrate he rela- 
tionship  between  tumorigenicity and at least one  meas- 
u r e  of genomic instability, CAD gene amplification. 
The  method  developed  in  this  study  provides a quan- 
titative, rapid indicator  of  tumorigenicity  and  should 
prove  useful in t rying to elucidate  the  underlying  basis 
of genomic  instability in neoplastic cells. 
Tumor cell heterogeneity is a universal property of neo- 
plastic tissue (1-3). As early as  the late 18OOs, morphologically 
distinct subpopulations of cells could be identified within a 
single tumor (1). Such heterogeneity now includes variation 
in antigenicity, enzymatic activities, drug resistance, growth 
characteristics, and most importantly,  metastatic ability (1). 
Genotypic variation within tumor cell populations has also 
been revealed by karyotypic and molecular analyses; chro- 
mosomal abnormalities including aneuploidy, translocations, 
deletions, and amplifications have been observed in  a variety 
of tumor cells (4, 5). Recent molecular studies have shown 
that these rearrangements,  as well as single base mutation, 
can  alter the expression of oncogenes (6). 
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Clinical investigations have documented that  this pheno- 
typic and genotypic variation within neoplastic populations 
is not  static: multiple and  independent changes accumulate 
and  result in increased variability within the population dur- 
ing tumor progression. This genomic instability has been 
observed in  a wide variety of tumor types and thus appears to 
also be a universal feature of neoplastic tissue (1, 7,8).  Based 
on these observations, it has been postulated that  it is the 
aquisition of this genetic instability which generates the het- 
erogenous population of the tumor and provides the material 
for secondary changes that result in  the malignant phenotype 
(9). Mutation  rates of normal and malignant cells have been 
compared to try and understand the relationship between 
genetic instability and tumorigenicity. Chinese hamster em- 
bryo fibroblasts show a higher spontaneous  mutation  rate to 
thioguanine resistance and ouabain resistance after the cells 
are doubly transformed with SV40 and polyoma virus (10). 
Singly transformed fibroblasts (polyoma only) show no in- 
crease in  mutation  rate. Similarly, murine fibrosarcoma cells 
with high metastatic ability have a higher mutation  rate (at 
these same two  loci) than cells with a low metastatic ability 
(11). Recent studies with human lymphocytes show that spon- 
taneously malignant tissue mutates to thioguanine resistance 
at a much higher rate than normal lymphocytes (12). In 
contrast,  a  nontransformed  human fibroblastic line was equiv- 
alent  to a  transformed  human line in the  rate of mutation to 
thioguanine and ouabain resistance (13). Taken together, 
these reports suggest a relationship between gene mutation 
rate and tumorigenicity. We have chosen to look at the 
incidence of a different endpoint of genomic instability, gene 
amplification, in an attempt to see if this also relates to 
tumorigenicity. Based on recent oncogene studies, one would 
expect the frequency of point  mutations, amplification, and 
rearrangements to correlate with tumorigenicity. 
We chose to study genetic instability using gene amplifi- 
cation  as  a  marker for several reasons. For several decades, 
the manifestations of gene amplification, homogeneously 
staining regions and double minute chromosomes, have been 
observed in neoplastic tissue, although at  the time the molec- 
ular basis of these chromosomal abnormalities was not known 
(14-16). In  the 1970s, studies by Beidler and co-workers (17) 
associated these chromosomal abnormalities with drug resist- 
ance; Schimke and co-workers (18-21) found that  the basis 
of the resistance in  this instance was an increase in gene  copy 
number (gene amplification). These observations prompted 
investigations into  the identity of the sequences which are 
carried on homogeneously staining regions and double minute 
chromosomes in human  tumor biopsy materials and led to  the 
discovery that oncogenes are often amplified, especially in 
certain  tumor types (22-25). Finally, gene amplification is an 
example of a genomic instability or rearrangement which is 
easy to measure on a molecular level. Unlike random chro- 
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mosomal breaks or translocations, amplification of a  targeted 
sequence can be measured using colony formation and easily 
verified by determination of gene  copy number. 
We chose to study genetic instability using PALA' resist: 
ance and  the ensuing amplification of the CAD gene, because 
unlike methotrexate resistance which may occur through mul- 
tiple mechanisms, the only reported mechanism of resistance 
to PALA is  through amplification of the CAD gene (26, 27). 
The CAD gene codes for the multifunctional CAD enzyme, 
and PALA inhibits the  aspartate transcarbamylase activity 
of this enzyme. Thus, in asking whether tumorigenic cells 
amplify DNA sequences more often that nontumorigenic cells, 
we used the incidence of resistance to PALA as  an indirect 
indicator of a cell's ability to amplify DNA. 
The cell lines used in  this report  are cloned lines of rat liver 
epithelial cells which were  developed to study the relationship 
between selected paratumorigenic phenotypes (such as growth 
in soft agar and differential isozyme expression) and the 
ability of these cells to form tumors when injected into new- 
born isogenic rats (28, 29). These investigations, performed 
with clonal subpopulations which vary in  their tumorigenicity 
(29), have shown conclusively that these phenotypic markers 
do not co-segregate precisely with tumorigenicity (30). The 
extensive characterization of this in vitro system qualifies 
these cells as ideal candidates for the  further investigation of 
the relationship between gene amplification and tumorigenic- 
ity. WB20 is a  nontransformed cell line derived from a normal 
adult rat liver which  was predominantly diploid (31). Trans- 
formation of this cell line with N-methyl-N'-nitro-N-nitro- 
soguanidine produced a phenotypically heterogeneous popu- 
lation from which  was isolated many subclones with altered 
properties resembling those seen in hepatocarcinogenesis in 
vivo (32). The cell lines designated GP and GN were selected 
from this population on the basis of whether they were his- 
tochemically y-glutamyl transpeptidase-negative (GN) or y- 
glutamyl transpeptidase-positive (GP). Cloned lines of GN 
and GP cells were propagated and extensively characterized 
for growth conditions, DNA content, isozyme profiles, and 
tumorigenicity (28, 29). Some of these cloned lines were used 
in this  study  and in parallel studies reconfirming tumorigenic- 
ity. 
In  this study, we have examined the relationship between 
genetic instability  and tumorigenicity using gene amplifica- 
tion  as  a marker for the genetic instability. Specifically, we 
have asked whether the ability of a cell to amplify DNA 
sequences correlates with its ability to form tumors. Our 
results  demonstrate  a  strong correlation between tumorigenic- 
ity  and at least one measure of genomic instability, CAD gene 
amplification. 
EXPERIMENTAL  PROCEDURES 
Cells and Culture Conditions-Rat liver epithelial cell lines were 
developed by Tsao et al. (32) and provided to us .by J. W. Grisham. 
All cell lines were  grown in complete medium consisting of: a-minimal 
essential medium (a-MEM) supplemented with 10% dialyzed fetal 
bovine serum (GIBCO), 100 units/ml penicillin, and 100  pg/ml strep- 
tomycin. Stock cell lines were used for a maximum period of 3  months, 
a t  which time frozen aliquots of cells were thawed for use in subse- 
quent experiments to minimize changes resulting from extended 
propagation. As an additional  control, dialyzed serum from a single 
lot was used in  all experiments. The aliquots of frozen cells used in 
these experiments were the same as those used for previous and 
ongoing tumorigenicity studies. At the conclusion of these experi- 
The abbreviations used are: PALA, N-(phosphonoacety1)-L-as- 
partate; CAD, an acronym for a multifunctional enzyme which con- 
tains  aspartate transcarbamylase activity; GN, y-glutamyl transpep- 
tidase-negative; GP, y-glutamyl transpeptidase-positive; LDm, lethal 
dose for 50% of the cellular population; kb, kilobase. 
ments, the aliquots were reconfirmed in their respective tumorigenic- 
ities. 
Plating Efficiencies and Cell Cycle  Times-To determine the plating 
efficiencies of unselected lines, 100 cells of each were seeded into 100- 
mm diameter dishes containing complete medium. After 8-10 h, this 
medium  was replaced with fresh medium to remove any unattached 
cells. Colonies appeared within 5-7 days; they were fixed with 3:l 
methano1:acetic acid, stained with 2% Giemsa (Gurr's), and those 
with greater than 50 cells were counted. The cell cycle time for each 
line was determined by plating cells into 100-mm diameter dishes at 
a density of 5 X 10' cells/dish. Each day, plates were trypsinized and 
the  total number of cells determined. The cell  cycle time presented 
in Table I is the time required for cells to double during exponential 
growth in complete medium. 
Drug Selectiorzs-For all selection experiments, cells were seeded 
into complete medium at  the appropriate density, allowed to  attach 
for 8-10 h, and  then exposed to PALA by replacing this medium with 
medium supplemented with the drug; PALA  was obtained from the 
Drug Evaluation  Branch of the National Cancer Institute  and Drs. 
Von  Hoff and Needham-VanDevanter. Except for additional replace- 
ments with fresh selection medium each week, cells grew undisturbed 
until colonies were  visible: colonies selected in low PALA concentra- 
tions (3 X LDW) were visible within 6-9 days; colonies resistant to 
higher concentrations required 2-4 weeks of growth. Colonies were 
then fixed, stained, and counted as described above. The incidence of 
PALA resistance (percent survival, Table 11) is the proportion of 
attached cells that gave rise to resistant colonies and, thus, is relative 
to  the plating efficiencies of the cells in medium without drug (100% 
survival). To minimize variation between experiments, these  plating 
efficiencies were determined independently and in  triplicate for each 
drug-selection experiment. LD, values (Table I) represent the con- 
centration of PALA that allows 50% survival and were estimated by 
interpolation from values of percent survival in 5, 10, and 20 p~ 
PALA; these values were determined in triplicate at both the begin- 
ning and end of our experiments. 
Subcloning PALA-resistant Lines-Cells from individual PALA- 
resistant colonies were carefully scraped from the bottom of 100-mm 
diameter culture dishes using a sterile micropipette tip and were 
collected in a 25-pl drop of PALA  medium. These cells were trans- 
ferred to a 24-well cloning dish (Falcon No. 3047) and expanded in 
the same concentration of PALA-containing medium (3 or 9 X LD6,J 
until  a total of 4 X lo' cells had been obtained. A small portion of 
these cells (10%) was frozen in 90% dialyzed serum, 10% dimethyl 
sulfoxide; genomic  DNA  was isolated from the remainder (see below). 
DNA  Cytojlourometric  Analysis-Cells  were prepared for analysis 
by the procedure of Gray and Coffino (33) with the following modi- 
fications: fixed cells were treated with 5 mg/ml RNase  A for 30 min 
at 37 "C and  then stained with 0.5 mg/ml propidium iodide for 30 
min at  room temperature. Cell suspensions (2-5 X 10' cells/ml) were 
kept on ice and analyzed at a flow rate of approximately 500 cells/s 
using a Becton-Dickinson FACS IV with an argon laser (488 nm). 
The average cellular DNA contents presented in Table  I  are relative 
to a karyotypically determined diploid (2n)  rat cell standard, WB- 
F344 (31). 
Molecular Analyses-Genomic  DNA  was isolated as described in 
Brown et al. (34). Briefly, cells were  lysed  by the addition of 0.01 M 
Tris-HC1 (pH 8), 0.01 M EDTA, 0.01 M sodium chloride, 0.02% sodium 
dodecyl sulfate, treated with proteinase K, extracted with 
pheno1:chloroform (l:l),  and treated with RNase A. DNA  was quan- 
titated spectrophotometrically and  the indicated amounts electropho- 
resed on 0.7% agarose gels after digestion with EcoRI. DNA was 
transferred to nitrocellulose (35) and hybridized to probes at  65 "C 
under standard conditions: 10-20 ng/ml probe DNA,  0.45 M sodium 
chloride, 0.045 M sodium citrate, 0.5% SDS, 2 X Denhardt's solution, 
and 50 pg/ml salmon sperm DNA. Radioactive probes were prepared 
by either nick translation  or randomly primed DNA synthesis  (mul- 
tiprime system, Amersham Corp.) using [32P]dCTP and had average 
specific activities of 10' cpm/pg and 10' countslminlpg, respectively. 
RESULTS 
Characteristics of Rat Liver Epithelial Cell Lines-The cell 
lines used in this  report  are cloned lines of rat liver epithelial 
cells which differ in their ability to form tumors when injected 
into newborn syngeneic rats. The  parental cell line, WB20, 
shows a fairly homogeneous morphology, exhibiting small 
polygonal cells of uniform size which grow in a monolayer. In 
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FIG. 1. Morphology of rat liver 
C, GP9.  Magnification 100 X: 
TABLE I 
Characteristics of rut  epithelial cell lines 
Cell line 
WB20 GP3  N5GP2  9  GN6
Tumorigenicity (%) 0 0 11  12.5 100 100 
Cell  cycle  time (h) 13  14 12  16 16 14 
Plating  efficiency (%) 78  26.5 84 48 57 50 
DNA content/cell 2.3n 2.8n 2.2n  3 6 1.9n 
LDm (PALA) (pM) 12.5  6 8 5  9 11 
a b c d  
i” i‘ 
1.0 0.9 1.0 
FIG. 2. Quantitation of CAD genes in unselected cell lines. 
Southern analysis of  rat  genomic  DNA  isolated  from  WB20 (lane a),  
GN5 (lane b) ,  and  GP9 cells (lanes c and d). The DNA  in  each  lane 
was digested with EcoRI. One portion of the blot (lanes a-c) was 
hybridized to probes  derived  from  both  a  hamster  CAD cDNA (52) 
and  a cDNA encoding  a  rat  androgen  binding  protein (53); the other 
(lane d )  was  hybridized to only the CAD  probe. The number at the 
bottom of each lane reflects the ratio between the intensities of 
hybridization of the 3.4-kilobase (kb) CAD fragment and the 6-kb 
androgen  binding  protein  fragment;  each  ratio has been  normalized 
to that obtained for WB20 (lane a). Values for the intensity of 
hybridization  were  determined  by desitometry  and were within the 
range showing  a  linear  relationship  between the amount of DNA in 
each  lane  and the amount  of  hybridization (not shown). 
contrast, the  GP  and GN cell lines are typified by varying 
amounts of heterogeneity in size, adhesion, and growth prop- 
erties. Fig. 1 shows the morphology of WB20,  GN5, and GP9, 
three of the six cell lines used in  this study. WB20 and  GP3 
cells  do not produce tumors when transplanted  into newborn 
syngeneic rats (Fischer 344), whereas the  other four lines used 
in this study produced tumors in 11-100%  of the recipients 
under identical conditions (see Table I and Ref.  29). Table I 
also shows growth parameters which are important in the 
determination of drug resistance. Although all of these lines 
are quite similar in their cell  cycle time, plating efficiency, 
and initial sensitivity to PALA, any differences evident in 
these determinations were accounted for in the assay for 
amplification ability (see  below). 
Previous characterizations of the DNA content of these cell 
lines have shown that cells of the GP subpopulations are 
typically hyperdiploid or hypotetraploid, whereas cells of the 
GN subpopulations are pseudodiploid (28). We  have redeter- 
mined the DNA content of the cell lines used in this study 
and confirmed the original observation (see Table I). The 
CAD copy number of the initial unselected population in 
three cell lines used in this study has been quantitated using 
Southern hybridization. Fig. 2 shows that  the WB20,  GN5, 
and GP9 cell populations unchallenged by  PALA each contain 
one genome equivalent of the CAD gene. 
Tumorigenicity and Drug Resistance-Using the cell lines 
described  above, the relationship between tumorigenicity and 
genetic instability was studied by determining the ability of 
each line to generate PALA-resistant colonies. To obtain 
initial estimates of the incidence of PALA resistance in these 
rat epithelial lines, cells from each line were seeded into 
culture dishes at several different densities and  then selected 
using medium with a PALA concentration equivalent to nine 
times  the LDw (9 X LDso) of each cell line; similar levels of 
this drug have previously been shown to provide selective 
pressure that  is ufficient to allow  only the growth of hamster 
cells having amplified CAD genes  (36). Results of this exper- 
iment indicated that tumorigenic cells give rise to colonies 
resistant to these drug levels  more often than nontumorigenic 
cells; representative culture dishes illustrating the difference 
between one of the most and least tumorigenic lines (GP9 
and WB20,  respectively) are shown in Fig.  3. To more  accu- 
rately define these differences,  cells  from each line were plated 
at  densities that yielded  between 10 and 100 colonies/culture 
dish upon selection. The incidences of  PALA resistance, 
calculated from the results of three independent experiments, 
are presented in Table I1 (percent survival at  9 x LDw). These 
results verified the striking differences  observed earlier, with 
the most tumorigenic cells forming resistant colonies 73 times 
more often than do cells that do not form tumors. Similar 
results were obtained when the  wB20, GN5, and GP9 cell 
populations were placed in the identical concentration of 
PALA (60 p ~ ) ;  the correlation with tumorigenicity held. The 
relative abilities to generate PALA-resistant colonies  was 1 X 
for the 0% tumorigenic WB20 line, 7 x for the 11% tumori- 
genic  GN5 line, and 65 X for the 100% tumorigenic GP9 line. 
In addition, both these results revealed a direct correlation 
between the degree of tumorigenicity of each cell line and  its 
ability to form resistant colonies. 
To determine the minimum concentration of PALA that 
would  show a similar relationship between these two  variables, 
three lines were selected with two  lower drug concentrations: 
3 X and 6 X LDw (Table 11). Selection with the  latter concen- 
tration showed a relationship similar to  that obtained for 9 X 
LDm, although the differences  between the lines were not as 
great. This relationship was not observed after selection at  
the lower concentration, 3 X LDw: although both tumorigenic 
lines formed resistant colonies more often that  the WB20 
line, the incidences of resistance of these lines was  no  longer 
directly correlated with their degree of tumorigenicity. 
Tumorigenicity and Amplification-To determine whether 
cells resistant to PALA had  amplified the CAD gene,  genomic 
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FIG. 3. Incidence of PALA resist- 
ance at 9 X LDao. PALA-resistant col- 
onies obtained after selection of lo5 
WB20 cells in 112.5 pM PALA ( A )  or 5 
X lo4 GP9 cells in 81 p~ PALA ( B ) ;  
LD50 for PALA is 12.5 and 9 pM for 
WB20 and GP9, respectively (see Table 
I). For each line, cells were seeded into 
100-mm diameter dishes containing 
complete medium. After 9 h, this me- 
dium was removed and replaced by me- 
dium supplemented with PALA. Except 
for additional replacements with fresh 
medium each week, cells were  allowed to 
grow undisturbed in the drug for approx- 
imately 4 weeks, fixed, and stained. For 
details see “Experimental Procedures.” 
TABLE I1 
Incidence of PALA resistance at 3, 6, and 9 X LDSO 
Cell line Tumorigenicity 
5%” 
Percent survival 
3 X LDW 6 X LDw 9 X LDw 
wB20 0 2.1 f O . l b  (1 xy 0.011 f 0.001 (1 x) 0.0013 & 0.0005 (1 X) 
GP3 0 NDd ND 0.0083 f 0.0007 (6 X) 
GN5 11 45.3 k 1.0  (22 x) 0.100 f 0.007 (9 X) 0.0242 f 0.0055 (18 X) 
GP2 12.5 ND ND 0.0431 f 0.0045 (33 X) 
GP9 100 16.4 f 0.8 (8 X) 0.253 f 0.023 (23 X) 0.0950 f 0.0042 (73 X) 
GN6 100 ND ND 0.0874 f 0.0051  (67 X) 
’ Tumorigenicity assayed in cells incubated in  trace amounts of serum (see Ref. 29). 
Mean f S.D.  of three independent  determinations, each performed in triplicate. 
For each drug  concentration, the values within the parentheses represent the relative incidences of resistance 
ND, not determined. 
to PALA normalized to  the WB20 value. 
A WB 20 B GP9 
3 X LD50 9 X LD5o 3 1  
a b c d e f g h   
I .-, r “-.’5fl””,m! x*.“- 
FIG. 4. CAD gene amplification in PALA-resistant subclones. A, eight independent subclones were 
expanded from individual PALA-resistant colonies selected from the WB20 line: four were resistant to PALA 
concentrations equivalent to 3 X LDso (lanes a-d), and four were resistant to 9 X LDW (lanes e-h). Genomic DNA 
from each subclone was isolated, digested with EcoRI, and 7.5 pg electrophoresed in a lane of a 0.7% agarose gel. 
DNA from this gel was transferred to nitrocellulose and hybridized to  the CAD probe; the 3.4-kb fragment revealed 
by this probe is shown (top).  This probe was then removed and  the filter rehybridized to probes derived from rat 
cDNAs encoding transforming growth factor-a (TGF-a) (54) and androgen binding protein (ABP); the 12-kb 
transforming growth factor-a and 16-kb androgen binding protein fragments revealed by these probes are shown 
(middle). B, Southern analysis of DNA from PALA-resistant subclones of the GP9 cell line; analysis is the same 
as  that performed in A. 
DNA from 16 independent, PALA-resistant lines (subclones) 
was analyzed for increases in gene  copy number; each of these 
subclones was expanded from individual PALA-resistant col- 
onies that had been chosen at random. Half of these sub- 
clones, four selected from the WB20 line and four from the 
GP9 line, were capable of growing in medium containing drug 
concentrations equivalent to 3 X the other half  were 
capable of growing in media containing drug concentrations 
equivalent to 9 x LD50. DNA from each subclone grown in  a 
drug concentration equivalent to  its respective 3 x LDN was 
hybridized to a CAD probe. Fig. 4 (lanes a-d) reveals that 
each had the same number of  CAD genes and  that  this number 
is the same as  the number quantitated in cells of the unse- 
lected population (data not shown). These results indicate 
that selection using low drug levels provides insufficient se- 
lective pressure for amplification; thus, the incidences of drug 
resistance for these lines at this concentration (Table 11, 
percent survival 3 X LDm) does not accurately reflect the 
ability of these lines to amplify the CAD  gene. In contrast  to 
the results obtained for 3 X LDN, similar analyses at  9 X LD50 
of four WB20 and four GP9 PALA-resistant subclones re- 
vealed that amplification of the CAD gene had occurred in 
each (Fig. 4, compare lanes e-h with lanes a-d); thus, growth 
of these cells in higher concentrations of PALA required 
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- CAD 
FIG. 5. Dilution analyses of the  extent of CAD amplification 
at 9 X LDao. A ,  Southern analysis of DNA from an unamplified 
WB20 line (lane a) and a WB20 subclone resistant to a PALA 
concentration equivalent to 9 X LD6o (lanes b-d). Lanes a and b 
contain 8.0 pg of DNA, lanes c and d contain 4.0 and 2.0 pg, 
respectively. This blot was hybridized to CAD and transforming 
growth factor-a probes; the fragments  revealed  by the CAD  probe  are 
indicated. B,  Southern analysis of DNA from an unamplified GP9 
line ( l a n e  a) and  a  subclone resistant to 9 X LD60 (lanes b-d); analysis 
is the same as that described  in  A. 
amplification of the CAD gene. The extent of CAD gene 
amplification in the WB20  subclones appeared to be  twice as 
great as that observed in the GP9 subclones; dilution analysis 
showed that the former had a 4-fold increase in CAD se- 
quences,  whereas the  latter showed a duplication of this gene 
(Fig. 5). Taken together, our results not only indicate that 
there is a striking parallel between the tumorigenic potential 
of these lines and  their ability to form PALA-resistant colo- 
nies but also  show that  the basis of this relationship lies in 
their abilities to amplify the CAD gene. 
DISCUSSION 
This report formally establishes the relationship between 
genomic instability, as measured by CAD gene amplification, 
and tumorigenicity. Our results show that  the ability of these 
rat liver epithelial cell lines to amplify the CAD gene is 
strongly correlated with their ability to form tumors after 
injection into day-old syngenic rats. GP9 cells, a highly tu- 
morigenic line, became resistant to PALA greater than 70 
times more often than those of the nontumorigenic WB20 
line; the incidences of CAD gene amplification in the other 
lines were also correlated with their degree of tumorigenicity 
and were thus intermediate to  the values obtained for GP9 
and WB20. Hybridization analyses of various probes to DNA 
from independent PALA-resistant subclones showed that  in 
each  case, resistance was due to CAD gene amplification; this 
result corroborates previous reports that amplification of this 
gene appears to be the only  mechanism of resistance to PALA. 
We believe that measurement of CAD gene amplification 
should provide a useful tool for examining the role that 
genomic instability plays in  the progression of normal cells to 
neoplastic cells. 
Recent studies of neoplastic cells  have  revealed that alter- 
ations in cellular proto-oncogenes can be created by point 
mutations, translocations, and amplification. Amplification 
of oncogenes has been  extensively studied and found to be a 
common  mechanism  for increased expression of these genes. 
Seeger and co-workers (37), for  example, found that 23 out of 
63 primary tumors of human neuroblastomas exhibited N- 
myc amplification and that amplification of this gene was 
most frequent in the tumors that were the most malignant. 
However, most studies to date do not suggest a mechanistic 
relationship between neoplastic transformation and amplifi- 
cation of oncogenes. Their studies have  shown  conclusively 
that variation in the expression of any one oncogene  is not a 
universal property of all tumor types (8, 37). Thus, in this 
study, we are not suggesting that amplification of any partic- 
ular gene is the cause of tumorigenicity but we suggest that 
gene amplification reflects the underlying genetic instability 
of a tumorigenic cell  which  allows it  to generate phenotypic 
diversity and progress to malignancy. 
Measuring the Incidence of  Gene Amplification-The advan- 
tages of using the method described in this report are several. 
First,  this assay is rapid. It consists of determination of the 
plating efficiency and LDm  followed  by subsequent determi- 
nation of the incidence of drug resistance (percent survival) 
at 9 X LDso. Although the time required for these measure- 
ments is dependent on the doubling times of the cells, deter- 
minations for the lines used in this study required only 
approximately 2 months. Second, this assay  is direct. Since 
amplification is the only reported mechanism  for resistance 
to PALA, complications in interpreting the underlying basis 
of resistance appear to be  avoided  by using this drug, thus 
allowing direct assessment of amplification ability from the 
incidence of drug resistance. Third,  this assay is quantitative; 
it allows the comparison of cell lines with differing growth 
properties or sensitivity to  the drug. Finally, this assay deter- 
mines the incidence of gene amplification in these cells in 
contrast to other studies (38,  39)  which  measure rate. Both 
values are determined by 1) the rate at which the cells are 
generated, 2) their intrinsic stability, and  3)  their g owth rates 
relative to  the rest of the cell population. This assay,  which 
measures incidence, accounts for these variables and provides 
a sensitive and direct measurement of gene amplification. 
Rate measurements, however,  have an additional component 
of time and  the preceding three variables should be taken  into 
account at each step  in  the selection (rate determination). 
In designing this assay to measure amplification ability in 
these lines, we wanted to develop as rapid an assay as possible. 
To  this end, we chose to use a single step selection  protocol 
and determine the minimal concentration of the selective 
drug that allowed the correlation of tumorigenicity with am- 
plification ability.  Cells  placed in a low stringency of selection 
(3 x LDso)  produced  colonies within 1 week. Rechallenging 
these colonies with the same drug concentration during clonal 
propagation revealed that a large proportion of the cells were 
killed, with the remainder (those used  for  molecular analyses) 
growing  very  slowly (data not shown). This result indicates 
that these cells  were not completely resistant to PALA but 
were  merely capable of tolerating the low drug concentrations. 
In contrast, cells  placed in a higher stringency of selection (9 
X LD50) take 2-4 weeks to emerge as colonies. Cells from 
virtually all of these colonies were resistant to killing and 
grew in the drug at  a rate similar to  that of unselected cells 
during clonal propagation (data not shown). These observa- 
tions are consistent with our results showing that subclones 
resistant to concentrations of  PALA equivalent to 3 X LDso 
were not amplified,  whereas those grown at  9 X LDso were 
amplified in each case  (Fig. 4). It is important to note that  at 
drug concentrations greater than 9 X LDso, greater amplifi- 
cation results and  the relationship between the incidence of 
drug resistance and tumorigenicity remains (data not shown). 
Two variables are especially important in the utilization of 
our method to determine amplification ability: the plating 
efficiency and LDm of each  line. The plating efficiency, the 
base line number of colonies obtained without selection (de- 
fined as 100% survival), is the value to which the number of 
colonies obtained after drug selection is compared. Overesti- 
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mating or underestimating this number would lead to an 
incorrect determination of the incidence of drug resistance. 
Likewise, accurate determination of the LD~o, the pivotal 
value for the final stringency of selection, is required. Table I 
shows that  the plating efficiencies and especially the LD,, 
values for the cell lines used in  this  study  are similar and only 
small adjustments were necessary to compare the  data be- 
tween cell lines. Even without  adjustments  (normalization to 
these values), the relationship between the ability to form 
tumors  and the ability to amplify held? 
Gene Amplification Correlates with Tumorigenicity-The 
correlation we find between PALA resistance and tumori- 
genicity in these cell lines is striking. Although amplification 
of the CAD gene is  the only reported mechanism of PALA 
resistance, we wanted to confirm that  the resistance to 9 X 
LDso of the different tumorigenic lines was due to amplifica- 
tion and did not result from a novel mechanism. Fig. 4 
demonstrates this point,  not only confirming that  the basis 
of the frequency of PALA resistance is  due  solely to amplifi- 
cation but also providing information on the  extent of gene 
amplification. We show that  the  extent of amplification is 
identical for each of the four subclones isolated from each line 
selected in 9 X LD~o. We also note that  the  extent of CAD 
gene amplification measured in the PALA-resistant WB20 
subclones is greater than that seen in the PALA-resistant 
GP9 subclones. Dilution  studies  demonstrate that  the WB20 
subclones are increased 4-fold in CAD gene copy number, 
whereas GP9 subclones are increased %fold in CAD gene copy 
number (Fig. 5). A trivial  explanation for the increase in CAD 
copy number, in  all of these subclones, could be  polyploidy of 
the cells. This  explanation  has been eliminated by the quan- 
titation  studies done in Fig. 4 showing an increase in CAD 
gene  copy number relatiue to two internal  standards: the gene 
coding for the  rat androgen binding protein  and that coding 
for transforming growth factor a. Polyploid cells would  show 
no  relatiue increase in  the CAD gene  copy number. In addition, 
we have performed flow cytometry on the PALA-resistant 
subclones to determine  their DNA contents.  Each subclone 
shows a DNA content identical to  that seen in  the unselected 
parent population as indicated in Table I. Thus, all available 
evidence points to gene amplification as the basis for the 
increase in CAD copy number and the  resultant resistance to 
PALA. Although it is clear that we are  not looking at poly- 
ploidy, the increase in gene copy number could be due to 
aneuploidy or  a duplication of the chromosomal arm which 
contains the CAD gene. Karyotyping of the resistant cell lines 
is now underway. Irrespective of how it arises, the correlation 
between the ability to increase the CAD copy number and  the 
ability to form tumors is strong. 
Could a greater cellular DNA content be the basis of the 
increased incidence of PALA resistance in the highly tumor- 
igenic GP9 cell line? We reject this  interpretation because we 
find the ploidy of the cell line does not predict its ability to 
amplify the CAD gene, whereas the tumorigenicity of the cell 
line does. We have extended our studies to a GN cell line 
which is comparable in tumorigenicity to GP9 (loo%), but is 
pseudodiploid (GN6),  and an additional GP cell line which is 
comparable to  the GN5 in tumorigenicity (11 uersus 12.5%) 
but is hyperdiploid (GP2).  In each instance, the incidence of 
PALA resistance co-segregates with tumorigenicity and  not 
with the pseudodiploid of hyperdiploid DNA content (see 
Table 11). Thus, although the extent of  CAD gene copy 
number may be related to the DNA content per cell, the 
ability to amplify the gene (the incidence of amplification) is 
not. 
A previous study  has reported accelerated evolution of drug 
resistance in a tumorigenic cell population based on a meas- 
urement of rate of dihydrofolate reductase gene amplification 
(38). In both that study and this one, similar conclusions 
about the role of genetic instability, as  it relates to tumori- 
genicity, were reached. Sager and co-workers (38) reported 
that  the rate of the evolution of methotrexate resistance was 
greater in one tumorigenic cell line than in its nontumorigenic 
counterpart. We attempted such a  rate analysis with our cell 
lines for both  methotrexate  and PALA resistance (data  not 
shown) and found no correlation between rate of amplification 
and tumorigenicity. We  believe that  this lack of correlation 
may be due to variables, such as cell cycle time, plating 
efficiency, or  drug sensitivity (see above), which  may change 
at each selection step  in the previously published method and 
are  not accounted for. A  further  basis for the lack of correla- 
tion may be due to our examination of a greater number of 
cell lines. The single step selection method used in  this study 
provides a  better approach because it  eliminates differences 
in cycle time, plating efficiency, and L D ~ o  which  would have 
to be recharacterized at each step in the multiple step method. 
The studies described herein,  as well as earlier observations, 
have reinforced the suggestion that genetic instability under- 
lies the neoplastic transformation of a cell. Our previous 
studies have shown several parallels between the evolution of 
a  drug-resistant population and  the evolution of a tumorigenic 
population. As they emerge, both generate a spectrum of 
chromosomal abnormalities which include translocations, 
chromosomal breakage, and  the production of extrachromo- 
somal DNA (4, 40-42).2 Both occur through step-wise proc- 
esses and produce widely heterogeneous populations which 
then progress through several step-wise selections to the 
terminal phenotype (43-45). Both  can be enhanced by treat- 
ment with carcinogens or tumor  promoters (46-49). In  addi- 
tion,  both the enhancement of dihydrofolate reductase ampli- 
fication (50) and chemical transformation of cultured cells 
(51)  are cell cycle-dependent. The emergence of drug  resist- 
ance is of major clinical importance; this study establishes 
that  the populations of cells that  are  the most tumorigenic 
are  the very populations of cells which develop drug resistance 
most readily. If  we can gain an  understanding of the molecular 
mechanisms which generate phenotypic diversity in tumor 
cells, it may be possible to modulate the frequency to  the 
benefit of therapeutic efficiency. The basis of the transition 
of a cell population from a regulated stable genome to  that of 
instability and heterogeneity typical of neoplastic and drug- 
resistant populations is unknown. Studies which contribute 
to  our  understanding of the cellular and biochemical control 
of gene amplification and how they relate to tumorigenicity 
may provide insights  into the molecular basis of this  transi- 
tion. 
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